69.98 0.00 (0.00%)
After hours: 4:37PM EDT
|Bid||69.25 x 1100|
|Ask||70.24 x 1200|
|Day's Range||69.64 - 70.57|
|52 Week Range||52.83 - 70.94|
|PE Ratio (TTM)||144.29|
|Earnings Date||Oct 25, 2018|
|Forward Dividend & Yield||1.92 (2.74%)|
|1y Target Est||72.88|
Accenture (ACN) has forecast its operating margin for fiscal 2018 at 14.8%, which would be higher than its fiscal 2017 margin of 12.9%. In the past five quarters, it mostly sustained a double-digit operating margin. In the chart below, you can see its GAAP operating margin trend in the last five quarters.
In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.
In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series: Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.
In this article, we’ll discuss the details of the dividends paid by pharmaceutical stocks Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
In the second quarter, Merck’s (MRK) Zepatier and Isentress reported revenues of $113.0 million and $305.0 million, respectively, which represented an ~78.0% decline and 8.0% growth on a YoY (year-over-year) basis. In the first half, Zepatier and Isentress reported net revenues of $243.0 million and $586.0 million, respectively.
As we discussed earlier, a few of the pharmaceutical stocks that have surpassed the returns of the S&P 500 Index YTD (year-to-date) include Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK). Let’s take a look at the details of their market caps.
Pharmaceutical ETFs are securities that are publicly traded on stock markets designed for investors who don’t have the capacity to hold many stocks but are interested in diversification within the pharmaceutical sector.
In August, the FDA approved Merck’s (MRK) and Eisai’s Lenvima in the first-line setting for the treatment of individuals with unresectable hepatocellular carcinoma (or HCC). The FDA’s approval of Lenvima in the first-line setting for the treatment of HCC was based on data from the REFLECT trial.
On September 12, Merck (MRK) announced that the FDA accepted for review the company’s new supplemental Biologics License Application (or sBLA) for the label expansion of Keytruda. Merck seeks label expansion of Keytruda for approval as a monotherapy in the first-line setting. This treatment is intended for individuals with metastatic nonsquamous or squamous NSCLC (non-small cell lung cancer) with tumors expressing PD-L1 without EGFR or ALK genomic tumor abnormalities.
Merck’s (MRK) Keytruda has witnessed ~89% YoY (year-over-year) growth and generated second-quarter revenues of $1.7 billion. In the US market, Keytruda’s second-quarter revenues grew 73.0% to reach $959.0.0 million. In the international markets, Keytruda’s revenues increased ~118.0% YoY to reach $707.0.0 million.
Merck (MRK) recently announced that its pivotal Phase 3 trial that evaluated Zerbaxa met its primary endpoint. Zerbaxa is an investigational antibiotic for the treatment of adult individuals with ventilated hospital-acquired bacteria pneumonia or ventilator-associated bacterial pneumonia (or VABP). Zerbaxa demonstrated non-inferiority compared to meropenem.
Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week
The index chalked up gains this week amid renewed hopes of trade talks between the United States and China.
On September 12, Allergan (AGN) announced the launch of Spotlyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit. Spotlyte is an innovative digital hub designed to educate consumers about medical aesthetic treatments. The below chart lists key updates on Spotlyte. Spotlyte is the first venture from Project Moonwalker and is designed to educate consumers about medical aesthetics.
Merck's (MRK) sBLA to include overall survival data from a key lung cancer study on Keytruda's label gets FDA's priority review. If approved, it will expand the eligible patient population.
Wall Street analysts estimate Thermo Fisher Scientific (TMO) to report 14.1% growth in revenues to ~$23.9 billion in full-year 2018 as compared to $20.9 billion during 2017. EPS is estimated to be $10.99 during 2018 as compared to EPS of $9.49 during 2017. Analysts estimate the net adjusted income to increase to $4.5 billion during 2018 as compared to the net adjusted income of $3.8 billion during 2017.
There are a number of reasons that attract investors towards large-cap companies such as Merck & Co Inc (NYSE:MRK), with a market cap of US$183.72b. Doing business globally, large capsRead More...
Roche Holding AG is refusing to cede the hottest new area of cancer care to Merck & Co. despite trailing its U.S. rival. Merck’s immune therapy Keytruda has dominated the market, with analysts predicting it will deliver more than $10 billion in annual sales by 2020. Roche still believes it can be a leader in the field of drugs designed to unleash the body’s immune system against tumors, with positive results for its own contender Tecentriq coming at two conferences this fall, Chief Executive Officer Severin Schwan said in an interview.
Merck's (MRK) label expansion study evaluating its antibacterial drug, Zerbaxa for two types of pneumonia infections meets primary endpoints.
Here we take a look at companies with approved immunotherapy therapies or pipeline candidates for the treatment of widely prevalent NSCLC.